In the present study, the therapeutic effects of GSK3β inhibition in ESCC cells included cell cycle arrest at G0/G1- and G2/M-phase, decreased expression of cyclin D1 and CDK4, and increased cyclin B1 expression. This evidence concerns the gene CDK4 and esophageal squamous cell carcinoma.